BioNTech’s Oncology Pipeline Shines at ASCO, but German Healthcare Reform Threatens Home Turf

BioNTech's promising cancer data contrasts with German government plans to slash healthcare spending, threatening pricing power and forcing site closures.

BioNTech finds itself in an awkward balancing act. Its cancer-fighting pipeline has delivered some of the most impressive clinical data in years, yet the company’s home market is simultaneously moving in the opposite direction. The German government’s plans to slash healthcare spending could severely curb the pricing power BioNTech will need when its first oncology products finally reach the market.

On the ASCO stage in Chicago, the Mainz-based biotech unveiled the tolerability edge of its antibody Pumitamig over Merck’s blockbuster Keytruda. In a Phase II trial testing Pumitamig in first-line non-small cell lung cancer, severe side effects occurred in about 44% of patients, but only 19% were directly attributed to the treatment. Jefferies analysts were quick to highlight that the discontinuation rate was numerically lower than the roughly 23% seen with Keytruda, calling the dataset “fully competitive” with late-stage candidates from current industry leaders. Meanwhile, the companion antibody Gotistobart showed sustained survival benefits in platinum-resistant ovarian cancer, with BMO Capital Markets arguing the market is underestimating the efficacy on display. A separate interim look at the ROSETTA Lung-02 study — run jointly with Bristol Myers Squibb — revealed that Pumitamig combined with chemotherapy achieved a 100% disease control rate across all subtypes and PD-L1 expression levels in advanced NSCLC.

Yet even as these data burnish BioNTech’s oncology credentials, Berlin is preparing to tighten the screws on drug pricing. The GKV-Beitragssatzstabilisierungsgesetz (GKV-BStabG) aims to squeeze nearly €20 billion out of the healthcare system by 2027 and more than €42 billion by 2030 through new price rules and mandatory rebates. BioNTech has joined a growing industry coalition protesting the plans, warning that the law could make Germany a less attractive launch market for novel cancer therapies. Eli Lilly has already announced it will halve its planned $2.5 billion investment in the country, cutting a large chunk of 1,000 planned jobs. For BioNTech, the timing could hardly be worse — the law is expected to pass before the summer recess and take effect in January 2027, right when the company hopes to begin commercialising its first oncology product.

Alongside the political headwinds, BioNTech is pushing through a radical internal restructuring. By the end of 2027, it will close three German sites — Idar-Oberstein, Marburg and Tübingen — along with a factory in Singapore, affecting up to 1,860 jobs. The company expects annual savings of around €500 million from 2029, which will be channelled into its oncology development. Critics argue that Germany is dismantling its biotech infrastructure just as the government makes investment conditions worse, a double blow to the sector.

The financial picture reflects the transition. First-quarter 2026 revenue slumped to €118.1 million, though management stuck to its full-year forecast of €2 billion to €2.3 billion. The balance sheet remains solid: €16.8 billion in cash and a $1 billion share buyback programme provide ample runway. But the stock market is taking a cautious view. Shares closed at €76.20 on Wednesday, down roughly 8% since the start of the year and still well below the 50-day moving average of about €81. Over the past twelve months, the stock has lost around 22% and sits nearly 28% below its 52-week high of €105.80.

Analyst opinion is split on the outlook. UBS upgraded BioNTech from Neutral to Buy after the ASCO presentations, lifting its price target from $117 to $135 and citing greater confidence in the late-stage oncology pipeline. Bernstein’s Jeffrey Walch struck a more cautious tone, initiating coverage with a Hold rating and a $96 target that offers little upside from current levels.

The pipeline itself remains exceptionally broad. More than 20 late-stage clinical trials are underway, including 13 registrational studies, and the company is targeting its first oncology product launch by the end of 2026. In the longer term, management aims to secure approvals for ten different cancer indications. At the annual general meeting in May, shareholders elected Iris Löw-Friedrich and Susanne Schaffert to the supervisory board, both bringing deep experience in clinical development and commercialisation of cancer therapies.

How the GKV-BStabG ultimately looks will determine the conditions under which BioNTech’s first wave of oncology products enters its most important European market. For now, the science is on track — but the politics remain a looming variable.